Efectividad farmacológica en el tratamiento agudo de la esquizofrenia. Revisión sistemática

• Helena Guerrero-Sabater ^[1] ; David Sancho-Cantus ^[2] ; Elena Castellano-Rioja ^[2]
  1. [1] Servicio de reanimación, Hospital Universitario y Politécnico la Fe (Valencia, España)
  2. [2] Departamento de enfermería,Facultad de Medicina y ciencias de la salud,Universidad Católica de Valencia San Vicente Mártir (Valencia, España)
• Localización: Presencia: Salud mental, investigación y humanidades, ISSN-e 1885-0219, Nº. 17, 2021
• Idioma: español
• Títulos paralelos:
  • Pharmacological effectiveness in the acute treatment of schizophrenia. A systematic review
• Enlaces
  • Texto completo
• Resumen
  • español

    Objetivo principal: La esquizofrenia es un trastorno psicótico funcional que cursa con ideas delirantes, alucinaciones y trastorno s d e l co mp o r-tamiento, pensamiento y percepción. Esta revisión tuvo como objetivo identificar el antipsicótico más idóneo para estabilizar y tratar la sintoma-tología aguda de la esquizofrenia. Metodología: se efectuó una búsqueda en las bases de datos PubMed, EBSCO, Web of Science y CUIDEN, y se empleó la metodología propuesta por el grupo PRISMA para seleccionar los textos más relevantes. Resultados princip ale s y co n clu sió n principal: 8 textos fueron seleccionados, y los hallazgos más relevantes señalan que no es posible afirmar cuál de los antipsicóticos co mp a ra -dos resulta más efectivo, y esto se debe principalmente a la gran heterogeneidad existente entre los diferentes tipos de estudios.

  • English

    Objective: Schizophrenia is a functional psychotic disorder that develops with delusional ideas, hallucinations, a n d b e h avio ra l, th o ug ht, a n d perception disorders. This review aimed to identify the most suitable antipsychotic to stabilize and treat acute schizophrenia sym p to ma tolo g y. Methods: A search was carried out on the PubMed, EBSCO, Web of Science and CUIDEN databases, and the methodology p r o po se d b y th e PRISMAgroup was used to select the most relevant ones. Results and conclusions: 7 texts were selected, and the most relevant findings in d i-cate that it is not possible to state which of the antipsychotics compared is most effective, and this is mainly due to thegreat heterogeneity between the different types of studies.

• Referencias bibliográficas
  • Biedermann F, Fleischhacker WW. Psychotic disorders in DSM-5 and ICD-11. CNS Spectrums. Cambridge University Press. 2016;21(4):349–54. https://doi.org/10.1017/S1092852916000316...
  • Tan N, van Os J. The schizophrenia spectrum and other psychotic disorders inthe DSM-5. Tijdschr Psychiatr. 2014;56 (3) :16 7-72. Dutch [internet]....
  • Zhang W, Lei D, Keedy SK, Ivleva EI, Eum S,Yao L, Tamminga CA, Clementz BA, Keshavan MS, Pearlson GD, Gershon ES, Bishop JR, Gong Q, Lui S,...
  • World Health Organization [internet]. Trastornos mentales. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/mental-disorders,...
  • Hany M, Rehman B, Azhar Y, et al. Schizophrenia. [internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishin g; 2 0 20 Jan-. Disponible...
  • World Health Organization [internet]. Esquizofrenia. Disponible en: https://www.who.int/topics/schizophrenia/es/,2020. [acceso: 02/04/2020]
  • Moreno B, Martín C, y Almenara J. Revisión crítica de las fuentes de variabilidad en la medición de la prevalencia de esquizofrenia. Salud...
  • Castro-de-Araujo LFS, Allin M, Picchioni MM, Mcdonald C, Pantelis C, Kanaan RAA. Schizophrenia moderates the relationship between white matter...
  • Bora E, Yücel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-5 c r ite ria and beyond.Schizophr...
  • Tomasella E, Bechelli L, Ogando MB, Mininni C, Di Guilmi MN, De Fino F, Zanutto S, Elgoyhen AB, Marin-Burgin A, Gelman DM. Deletion of dopamine...
  • Åsa Blomström, Håkan Karlsson, Renee Gardner, Lena Jörgensen, Cecilia Magnusson, Christina Dalman, Associations Between Maternal Infection...
  • Vaucher, J., Keating, B., Lasserre, A.et al.Cannabis use and risk of schizophrenia: a Mendelian r a n domiza tion s tudy .Mo l Psychiatry....
  • ArchibaldL, Brunette MF, Wallin DJ, Green AI. Alcohol Use Disorder and Schizophrenia orSchizoaffective Disor-der.Alcohol Res. 2019;40(1):...
  • Molteni S, Filosi E, Mensi MM, Spada G, Zandrini C, Ferro F, Paoletti M, Pichiecchio A, Bonoldi I, Balottin U. Predictors o f Outcomes in...
  • Fusar-Poli P, Davies C, Rutigliano G, Stahl D, Bonoldi I, McGuire P. Transdiagnostic Individualized Clin ically Ba s e d Ris k Calculator...
  • Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. 2014;39(9):638-45. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159061/....
  • Opare-Addo MNA, Mensah J, Aboagye GO. A Case of Schizophrenia in a Young Male Adult with no His to ry o f Su b stan ce Abuse: Impact ...
  • Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. The neurobiology of treat-ment-resistant schizophrenia:...
  • Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication Adherence an d Dis c ontinua tion o f Ar ipipr az ole Once-Monthly 400mg...
  • HsuHF, Kao CC, Lu T, Ying JC, Lee SY. Differences in the Effectiveness of Long-Acting Injection and Orally Administere d Antipsychotics in...
  • Emsley R, Kilian S. Efficacy and safety profile of paliperidone palmitate injections in the management of patients with s ch iz -ophrenia:...
  • Ogrinc G, Davies L, Goodman D, BataldenP, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Impro ve ment Re -porting Excellence):...
  • Sağlam Aykut D. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Med ic atio n Adherence, Side ...
  • Lynn Starr H, Bermak J, Mao L, Rodriguez S, Alphs L. Comparison of long-acting and oral antipsychotic treatment effects in patients with...
  • Detke HC, Weiden PJ, Llorca PM, Choukour M, Watson SB, Brunner E, Ascher-Svanum H. Comparison of olanzapine long-acting injection and oral...
  • Malla A, Chue P, Jordan G, Stip E, Koczerginski D, Milliken H, Joseph A, Williams R, Adams B, Manchanda R, Oyewumi K, Roy MA. An Exploratory,...
  • Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller d e l D, Severe JB, Wilson DR,...
  • Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus o ral antipsychotics: A meta-analysis...
  • Subotnik KL, Casaus LR, Ventura J, et al. Long-Acting Injectable Risperidone for Relapse Prevention and Contr ol o f Breakthrough Symptoms...
  • Hervás G, Ruano C, Sanz_Alfayate G, Algora I, Celdrán MAMur MA.Análisis del manejo de antipsicóticos inyectables de larga duración en varios...
  • Kane JM, Sanchez R, Zhao J, Duca AR, Johnson BR, McQuade RD, Eramo A, Baker RA, Peters-Strickland T. Hospitalisation rates in patients switched...
  • Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. or al a n tips ych otic medications...
  • Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does Half-Life Matter After Antipsychotic Discontinuation ? A Relapse Comparison...
  • Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L. Benefit-risk assessment of paliperidone or al e x te nde d-re le as e tablet versus...
  • Alphs L, Bossie C, Mao L, Lee E, Starr HL. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients withrecent-onset...
  • Kwon JS, Kim SN, Han J, Lee SI, Chang JS, Choi JS, Lee HJ, Cho SJ, Jun TY, Lee SH, Han C, Lee KU, Lee KK, Lee E. Satisfaction of immediate...
  • Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy...
  • Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schiz-ophrenia. Early...
  • Sağlam Aykut D. Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects,...
  • Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. The Use of Long-Acting Injectable Anti-psychotics in Schizophrenia:...
  • Castillo EG, Stroup TS. Effectiveness of long-acting injectable antipsychotics: a clinical perspective. Evidence-bas ed Me n tal Health. 2015;18(2):36-39....
  • Lynn Starr H, Bermak J, Mao L, Rodriguez S, Alphs L. Comparison of long-acting and oral antipsychotic treatment effects in patients with...
  • Alphs L, Schooler N, Lauriello J. How study designs influence comparative effectiveness outcomes: The cas e o f o ra l v er su s long-acting...
  • Wykes T, Rose D, Williams P, David AS. Working alliance and its relationship to outcomes in a randomized contro lled tr ial (RCT) of antipsychotic...
  • Crespo-Facorro B, Bernardo M, Argimon JM, Arrojo M, Bravo-Ortiz MF, Cabrera-Cifuentes A, Carretero-Román J, Fr a n co-Martín MA, García-Portilla...